

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/497,422	02/03/2000	Stephen A. Berry	ARC2914 US R1 (3139-6169U		
7590 10/19/2005			EXAMINER		
Edgar R. Cataxinos			FUBARA, BLESSING M		
TraskBritt, PC PO Box 2550			ART UNIT	PAPER NUMBER	
Salt Lake City,	UT 84110	1618	1		
		DATE MAILED: 10/19/200.	5		

Please find below and/or attached an Office communication concerning this application or proceeding.

	· · · · · · · · · · · · · · · · · · ·	Applic	ation No.	Applicant(s)				
Office Action Summary		09/497	7,422	BERRY, STEPHEN				
		Examii	ner	Art Unit				
			g M. Fubara	1618				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
2a)☐ 3)☐	 1) Responsive to communication(s) filed on <u>27 September 2005</u>. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213. 							
Disposition of Claims								
5)	Claim(s) 10,11,15-18,21-23,27,29-32,35 (a) Of the above claim(s) is/are w Claim(s) 10,11 and 15 is/are allowed. Claim(s) 16-18,21-23,27,29-32,35-38 ar Claim(s) is/are objected to. Claim(s) are subject to restriction on Papers The specification is objected to by the Ex The drawing(s) filed on is/are: a)[vithdrawn from and 46-48 is/are and/or election caminer. accepted or	consideration. rejected. n requirement. b) objected to by the	Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	nder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-station Disclosure Statement(s) (PTO-1449 or PTO No(s)/Mail Date 09/27/05.		4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:	ate	-152)			

Application/Control Number: 09/497,422 Page 2

Art Unit: 1618

DETAILED ACTION

Examiner acknowledges receipt of request for extension of time, IDS and request for continued examination under 37 CFR 1.114, all filed 09/27/2005. Claims 10, 11, 15-18, 21-23, 27, 29-32, 35-38 and 46-48 are pending.

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants' submission filed on 09/27/05 has been entered.

Response to Amendment

The amendment filed 08/01/05 is further considered. The comprising language of claims 16-18, 21-23, 27, 29-33, 35-38 and 46-48 remain open.

Allowable Subject Matter

Claims 10, 11 and 15 are allowable because the prior art does not disclose compositions consisting of polyvinylpyrrolidone, glycerol monolaurate and lauryl lactate; or composition consisting of polyvinylpyrrolidone, polysorbate and lauryl lactate; or the composition of claim 15.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

Art Unit: 1618

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

3. Claims 16-18, 21-23, 27, 29-32, 35-38 and 46-48 are rejected under 35 U.S.C. 103(a) as being unpatentable over Daher et al. (US 4,376,118) and Yajima et al. (US 5,972,373).

Daher discloses non-aqueous solution of tetracycline that comprises N-methyl-2pyrrolidone, lauryl lactate, antioxidant, polysorbate solubilizer (abstract, column 1, lines 52 and 58; column 2, lines 6-12). The tetracycline composition of Daher does not contain polyvinylpyrrolidone. But, Yajima discloses a composition that contains tetracycline (column 2, lines 42 and 43), glycerol monolaurate or glycerol monostearate (column 2, lines 49-53), excipients (column 3, lines 19-29), disintegrants (column 3, lines 30-34), polyvinylpyrrolidone (column 3, line 38), antioxidant (column 3, lines 41-45), cellulose materials and dyes (column 3, lines 49-60) and polysorbate or polyoxyethylene-polyoxypropylene block copolymers (column 3, lines 61-65). The compositions of Daher and Yajima individually contains tetracycline antibiotic. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose....[T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). The viscosity recited is a property of the composition. There does not appear to be demonstration that the viscosity provides unusual results to the recited composition. And a composition/vehicle comprising polyvinylpyrrolidone, lauryl lactate and glycerol monolaurate or polysorbate would necessarily have the recited viscosity and there is no demonstration in applicants' disclosure that the viscosity conveys special results/effects to the composition. In

Application/Control Number: 09/497,422

Art Unit: 1618

the absence of a showing, the recited viscosity is not critical to a composition/vehicle that comprises polyvinylpyrrolidone, polysorbate or glycerol monolaurate, and lauryl lactate.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to combine the composition of Daher and Yajima to form a third composition. One having ordinary skill in the art would have been motivated to combine the separate compositions of Daher and Yajima to form a third composition comprising tetracycline antibiotic, polyvinylpyrrolidone, polysorbate, lauryl lactate, glycerol monolaurate and excipients and antioxidants with the expectation that the third composition would be useful as an antibiotic composition (In re Kerkhoven). The comprising language of the claims allows for the presence of other ingredients in the composition of the cited prior art.

Applicants' argument filed 08/01/05 and remarks foiled 08/01/05 have been considered but the argument that the combined references do not disclose the claimed invention in claims 16-18, 21-23, 27, 29-32, 35-38 and 46-48 is not persuasive because the comprising language of said claims is open.

4. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The previously cited art, Farinas et al. (US 5,928,666), Lyle (US 5,814,323) and reference to Farinas et al. cited by applicants on Form PTO-1449 (US 5,906,830) are art of interest.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 3:30 p.m. (Monday to Friday).

Application/Control Number: 09/497,422 Page 5

Art Unit: 1618

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Blessing Fubara

mstubura

Patent Examiner Tech. Center 1600